MCM
SRPT icon

Mazama Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Mazama Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-3,848
Closed -$56K – 296
2014
Q4 		$56K Buy
+3,848
New +$65.2K 0.01% 223

Other funds holding SRPT

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Mazama Capital Management's SRPT Position: Q1 2015 in Review

Mazama Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2015, closing a stake of 3,848 shares — an estimated $56K sold.

Mazama Capital Management first reported a position in SRPT in Q4 2014 and held it in 1 quarter. The position peaked at $56K in Q4 2014. 114 funds tracked by Wall St. Rank hold SRPT as of Q1 2015.

  • Mazama Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Mazama Capital Management sold 3,848 Sarepta Therapeutics shares in Q1 2015, an estimated $56K.
  • Mazama Capital Management first reported a position in Sarepta Therapeutics in Q4 2014 and held it in 1 quarter.
  • Mazama Capital Management's Sarepta Therapeutics position peaked at $56K in Q4 2014.
  • 114 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2015.

Based on Mazama Capital Management's 13F filing for Q1 2015, filed 15 May 2015.